Cosmo Pharmaceuticals N.V. (CMOPF)
USD 66.93
(0.0%)
USD 66.93
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.83 Million EUR | -99.05% |
| 2022 | 192.85 Million USD | -4.03% |
| 2021 | 200.94 Million USD | -6.24% |
| 2020 | 214.31 Million USD | 15.83% |
| 2019 | 185.02 Million USD | 2.35% |
| 2018 | 180.78 Million EUR | 3263.66% |
| 2017 | 5.37 Million EUR | -4.02% |
| 2016 | 5.59 Million EUR | -36.62% |
| 2015 | 8.83 Million EUR | -19.17% |
| 2014 | 10.93 Million EUR | -6.96% |
| 2013 | 11.74 Million EUR | -8.48% |
| 2012 | 12.83 Million EUR | 489.94% |
| 2011 | 2.17 Million EUR | -37.78% |
| 2010 | 3.49 Million EUR | 17.51% |
| 2009 | 2.97 Million EUR | -30.69% |
| 2008 | 4.29 Million EUR | -17.39% |
| 2007 | 5.19 Million EUR | -12.08% |
| 2006 | 5.91 Million EUR | -72.58% |
| 2005 | 21.55 Million EUR | 11.46% |
| 2004 | 19.34 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 851 Thousand EUR | -53.72% |
| 2024 Q2 | 1.45 Million EUR | 70.98% |
| 2023 Q2 | 198.98 Million USD | 13.86% |
| 2023 FY | 1.83 Million EUR | -99.05% |
| 2023 Q1 | 174.76 Million EUR | -9.38% |
| 2023 Q3 | 1.07 Million EUR | -99.46% |
| 2023 Q4 | 1.83 Million EUR | 70.44% |
| 2022 Q4 | 192.85 Million USD | 11.58% |
| 2022 FY | 192.85 Million USD | -4.03% |
| 2022 Q1 | 189.23 Million EUR | 11.37% |
| 2022 Q2 | 179.85 Million EUR | -4.95% |
| 2022 Q3 | 172.84 Million EUR | -3.9% |
| 2021 Q1 | 195.82 Million EUR | 16.46% |
| 2021 FY | 200.94 Million USD | -6.24% |
| 2021 Q2 | 168.11 Million EUR | -14.15% |
| 2021 Q3 | 195.92 Million EUR | 16.54% |
| 2021 Q4 | 169.91 Million EUR | -13.27% |
| 2020 Q4 | 168.14 Million EUR | -13.27% |
| 2020 FY | 214.31 Million USD | 15.83% |
| 2020 Q2 | 168.01 Million EUR | -7.68% |
| 2020 Q3 | 193.87 Million EUR | 15.39% |
| 2020 Q1 | 181.99 Million EUR | 10.41% |
| 2019 Q3 | 178.18 Million EUR | 8.87% |
| 2019 FY | 185.02 Million USD | 2.35% |
| 2019 Q1 | 181.99 Million EUR | 15.08% |
| 2019 Q2 | 163.67 Million EUR | -10.07% |
| 2019 Q4 | 164.83 Million EUR | -7.49% |
| 2018 FY | 180.78 Million EUR | 3263.66% |
| 2018 Q3 | 183.13 Million EUR | 4194.84% |
| 2018 Q2 | 4.26 Million EUR | -10.62% |
| 2018 Q1 | 4.77 Million EUR | 6.59% |
| 2018 Q4 | 158.15 Million EUR | -13.64% |
| 2017 Q4 | 4.47 Million EUR | -6.95% |
| 2017 Q2 | 4.93 Million EUR | 5.88% |
| 2017 Q1 | 4.65 Million EUR | -12.28% |
| 2017 FY | 5.37 Million EUR | -4.02% |
| 2017 Q3 | 4.81 Million EUR | -2.45% |
| 2016 Q4 | 5.3 Million EUR | 3.33% |
| 2016 Q2 | 7.41 Million EUR | 9.64% |
| 2016 Q1 | 6.76 Million EUR | -16.82% |
| 2016 FY | 5.59 Million EUR | -36.62% |
| 2016 Q3 | 5.13 Million EUR | -30.73% |
| 2015 Q2 | 9.96 Million EUR | 8.51% |
| 2015 FY | 8.83 Million EUR | -19.17% |
| 2015 Q4 | 8.13 Million EUR | 8.98% |
| 2015 Q3 | 7.46 Million EUR | -25.1% |
| 2015 Q1 | 9.18 Million EUR | -15.99% |
| 2014 FY | 10.93 Million EUR | -6.96% |
| 2014 Q4 | 10.93 Million EUR | -9.23% |
| 2014 Q3 | 12.04 Million EUR | 11.33% |
| 2014 Q2 | 10.81 Million EUR | -17.0% |
| 2014 Q1 | 13.03 Million EUR | 10.92% |
| 2013 Q3 | 14.09 Million EUR | 11.42% |
| 2013 FY | 11.74 Million EUR | -8.48% |
| 2013 Q4 | 11.74 Million EUR | -16.67% |
| 2013 Q2 | 12.65 Million EUR | -13.0% |
| 2013 Q1 | 14.54 Million EUR | 13.29% |
| 2012 Q4 | 12.83 Million EUR | 0.0% |
| 2012 Q2 | 1.77 Million EUR | 0.0% |
| 2012 FY | 12.83 Million EUR | 489.94% |
| 2011 Q2 | 2.73 Million EUR | 0.0% |
| 2011 FY | 2.17 Million EUR | -37.78% |
| 2011 Q4 | 2.17 Million EUR | 0.0% |
| 2010 Q2 | 4.46 Million EUR | 0.0% |
| 2010 Q4 | 3.49 Million EUR | 0.0% |
| 2010 FY | 3.49 Million EUR | 17.51% |
| 2009 FY | 2.97 Million EUR | -30.69% |
| 2009 Q4 | 2.97 Million EUR | 0.0% |
| 2008 FY | 4.29 Million EUR | -17.39% |
| 2007 FY | 5.19 Million EUR | -12.08% |
| 2006 FY | 5.91 Million EUR | -72.58% |
| 2005 FY | 21.55 Million EUR | 11.46% |
| 2004 FY | 19.34 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 99.994% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 99.996% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | 98.154% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | 95.649% |
| Novartis AG | 26.34 Billion USD | 99.993% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | 95.449% |